DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2016/0279056A1 Zhao Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2016/0279056A1 Zhao Et Al US 20160279056A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0279056A1 Zhao et al. (43) Pub. Date: Sep. 29, 2016 (54) LIQUISOFT CAPSULES Publication Classification (71) Applicant: BANNER LIFE SCIENCES LLC, (51) Int. Cl. High Point, NC (US) A6IR 9/00 (2006.01) A 6LX 9/50 (2006.01) (72) Inventors: Yinyan Zhao, Greensboro, NC (US); A63L/46.5 (2006.01) Yunhua Hu, Cary, NC (US); Mervin A6II 3L/28 (2006.01) Williams, JR., Jamestown, NC (US); A6II 45/06 (2006.01) Tatyana Dyakonov, Greensboro, NC A63L/485 (2006.01) (US); Saujanya Gosangari, Jamestown, (52) U.S. Cl. NC (US); Chue Yang, Greensboro, NC CPC ............. A61K 9/0056 (2013.01); A61K 45/06 (US); Henricus Marinus, Gerardus, (2013.01); A61K 31/485 (2013.01); A61 K Maria Van Duijnhoven, den Bosch 3 1/465 (2013.01); A61 K3I/28 (2013.01); (NL); Martin Piest, Tilburg (NL); A61K 9/5057 (2013.01); A61K 9/5052 Aqeel A Fatmi, High Point, NC (US) (2013.01); A61K 9/5089 (2013.01) (57) ABSTRACT (21) Appl. No.: 15/080,614 Described herein are oral pharmaceutical compositions Suit able for chewing, Sucking, or buccal dissolution comprising (22) Filed: Mar. 25, 2016 Soft gel capsules and liquid fills, methods for making the same, and methods for treating Subjects in need thereof with Related U.S. Application Data Such capsules. In particular, oral pharmaceutical composi (60) Provisional application No. 62/236,297, filed on Oct. tions comprising chewable. Suckable, or dissolvable soft gel 2, 2015, provisional application No. 62/138,468, filed capsules with various flowable fill compositions are on Mar. 26, 2015. described. Patent Application Publication Sep. 29, 2016 US 2016/0279056A1 FIGURE 1 120 1OO 60 40 O 2O 40 60 Time (min) US 2016/0279056A1 Sep. 29, 2016 LIQUISOFT CAPSULES properties that can be sucked or that slowly dissolve in the mouth to release pleasant-tasting or refreshing liquid fills. CROSS REFERENCE TO RELATED APPLICATIONS SUMMARY 0001. This application claims priority to U.S. Provisional 0008. One embodiment described herein is an oral phar Patent Application Nos. 62/138,468, filed on Mar. 26, 2015, maceutical composition Suitable for chewing, Sucking, or and 62/236,297, filed on Oct. 2, 2015, each of which is buccal dissolution comprising a soft capsule with a flowable incorporated herein in its entirety by express reference fill comprising one or more active pharmaceutical ingredi thereto. This application is related to International Patent ents, nutraceuticals, flavors, or refresheners. Exemplary Application No. PCT/US2016/ , filed on Mar. 25, embodiments are cough and cold over-the-counter (OTC) 2016, which is incorporated herein in its entirety by express remedies; nonsteroidal anti-inflammatory drugs (NSAIDs) reference thereto. for treating pain; nicotine satiation, nicotine-replacement therapy, or Smoking cessation therapy; breath fresheners or TECHNICAL FIELD treatments for halitosis; treatments for temporary discom forts of the stomach and gastrointestinal tract; or as a 0002. Described herein are oral pharmaceutical compo delivery means for any of the active pharmaceuticals sitions suitable for chewing. Sucking, or buccal dissolution described herein. comprising soft gel capsules and liquid fills, methods for 0009. Another embodiment described herein is an oral making the same, and methods for treating Subjects in need pharmaceutical composition Suitable for chewing, sucking, thereof with Such capsules. In particular, oral pharmaceuti or buccal dissolution comprising a shell encapsulating a cal compositions comprising chewable. Suckable, or dissolv matrix, the shell comprising: (a) one or more film-forming able softgel capsules with various flowable fill compositions polymers; (b) one or more plasticizers; (c) one or more are described. polymer modifiers; (d) one or more first Sweeteners; (e) one or more first solvents, (f) optionally, one or more excipients; BACKGROUND and a matrix comprising: (g) one or more hydrophilic 0003 Chewable dosage forms are typically manufactured vehicles: (h) one or more flavors: (i) one or more second as Solids, such as chewable tablets, or elastic semi-solids Sweeteners; () one or more second solvents; (k) one or more Such as chewing gums, molded gels, or chewable soft gelatin active pharmaceutical ingredients; and (1) optionally, one or capsules. While elastic semi-solid forms provide better more excipients. In one aspect describe herein, the film mouth feel and customer acceptance, chewable soft gelatin forming polymer comprises one or more of gelatin, partially capsules (e.g., "soft gels') have a benefit of being ingestible hydrolyzed gelatin, hydrolyzed gelatin, hydrolyzed colla and can deliver accurate amounts of active ingredients to the gen, or combinations thereof. In another aspect describe oral cavity and digestive system. herein, the plasticizer comprises one or more of glycerol, maltitol, mannitol. Xylitol, lycasin, or combinations thereof. 0004 Soft gels have gained popularity and acceptance In another aspect describe herein, the polymer modifier due to their elegant and clear gelatin shells. Furthermore, comprises one or more of citric acid, acetic acid, lactic acid, softgel capsules are uniform, stable, dissolve quickly, allow malic acid, tartaric acid, or combinations thereof. In another for liquid formulations, and are easier for most Subjects to aspect describe herein, the hydrophilic vehicle comprises swallow. propylene glycol, polyethylene glycol 400, polyvinylpyr 0005 Soft gel capsules are typically formed of a capsule rolidone K30, glycerin, sorbitol, xylitol, maltitol, or combi shell encapsulating a liquid matrix fill. Several types of soft nations thereof. In another aspect describe herein, the first gel capsules can be chewed by the user. See e.g., U.S. Pat. Sweetener comprises sucralose, aspartame, Stevia, acesul Nos. 6,258,380; 8,097,279; 8,241,665; 8,414,916; and fame potassium, Xylitol, or combinations thereof. In another 8.765,174. Such chewable soft capsules are chewed by the aspect describe herein, the flavoring comprises citric acid, subject to release the fill contents into the mouth, instead of lactic acid, sodium citrate, orange flavor, eucalyptol, pep swallowing the capsule with the fill still encapsulated within permint oil, methyl salicylate, glycine, or combinations the shell. Often the fill of chewable soft capsules contains thereof. In another aspect describe herein, the second sweet Substantial amounts of gelatin giving the fill a semi-solid ener comprises mannitol, maltitol, Xylitol, thaumatin, gly characteristic, rather than a true liquid character. cyrrhizic acid salts, acesulfame potassium, acesulfame salts, 0006 Although chewable soft capsules provide an effec Sucralose, aspartame, Stevia, or combinations thereof. In tive dosage system, user acceptance has been limited by the another aspect describe herein, the active pharmaceutical organoleptic properties of the capsules, which are some ingredient comprises one or more of astemizole, azelastine, times criticized as being leathery or rubbery. Chewable soft aZatadine, brompheniramine, carbinoxamine, cetirizine, capsules sometimes have a distinguishable difference chlorpheniramine, clemastine, cyproheptadine, deslorata between the shell and fill in terms of texture and mouth-feel. dine, dexbrompheniramine, dexchlorpheniramine, diphen Some users experience difficulty consuming the masticated hydramine, fexofenadine, hydroxy Zine, levocetirizine, lor sheath after the internal fill has been released. In addition, atadine, phenindamine, pheniramine, phenyltoloxamine, chewable soft capsules tend to harden over time. promethazine, pyrilamine, terfenadine, tripelennamine, 0007 Thus, there is an unmet need for chewable soft triprolidine, acetyl dihydrocodeine, benproperine, benzona capsule dosage forms comprising liquid fills, where the tate, benzylmorphine, bibenzonium bromide, butamirate, capsule shell can be chewed. Sucked, or that dissolves in the butorphanol, carbetapentane, chlophedianol, clobutinol, mouth and releases the active ingredient in a liquid form in clofedanol, cloperastine, codeine, dextromethorphan, dex the oral cavity. Accordingly, it is desirable to develop tromethorphan hydrobromide, diacetylmorphine, dibunate, chewable soft gelatin capsules having desirable organoleptic dihydrocodeine, dimemorfan, dimethoxanate, diphenhy US 2016/0279056A1 Sep. 29, 2016 dramine, dropropizine, droxypropine, ethylmorphine, fedri choline magnesium salicylate, diclofenac, diflunisal, etod late, glaucine, hydrocodone, hydromorphone, isoaminile, olac, etoricoxib, faislamine, fenbufen, fenoprofen, flurbipro laudanum, levodropropizine, levomethadone, levopropoxy fen, indometacin, ketoprofen, ketorolac, lornoxicam, loXo phene, meprotixol, methadone, morclofone, nepinalone, profen, meloxicam, meclofenamic acid, mefenamic acid, nicocodine, nicodicodine, normethadone, noscapine, oxela meloxicam, metamizole, methyl salicylate, magnesium din, oxolamine, pentoxyverine, pholcodine, pipaZetate, pip salicylate, nabumetone, naproxen, nimeSulide, paracetamol. eridione, prenoxdiazine, tipepidine, Zipeprol, acetylcysteine, oxyphenbutaZone, parecoxib, phenylbutaZone, piroxicam, althea root, ambroXol, antimony pentasulfide, bromhexine, salicyl salicylate, Sulindac, Sulfinpyrazone, Suprofen, tenoxi carbocisteine, cineole, combinations, combinations, creo cam, tiaprofenic acid, tolmetin, Valdecoxib, acetylsalicylic Sote, dembrexine hydrochloride, domiodol, dornase alfa, acid, aloxiprin, aminophenaZone, anilides, benorilate,
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Pharmaceutical Manufacturing Formulations Liquid Products V () L UME Sarfaraz K
    HANDBOOK OF Pharmaceutical Manufacturing Formulations Liquid Products V () L UME Sarfaraz K. Niazi CRC PRESS Boca Raton London New York Washington, D.C. Table of Contents PART I Regulatory and Manufacturing Guidance 1 Chapter 1 Current Good Manufacturing Practice Considerations in Liquid Manufacturing 3 I. Introduction 3 II. Facilities 3 III. Equipment 3 IV. Raw Materials 4 V. Compounding 4 VI. Microbiological Quality 4 VII. Oral Suspensions 5 VIII. Product Specifications 5 IX. Process Validation 5 X. Stability 5 XI. Packaging 6 Chapter 2 Stability Testing of New Drug Substances and Products 7 I. Introduction 7 II. Drug Substance 7 A. General Case 8 B. Drug Substances Intended for Storage in a Refrigerator 8 C. Drag Substances Intended for Storage in a Freezer 8 D. Drug Substances Intended for Storage below -20°C 9 HI. Drag Product 10 A. General Case •' B. Drag Products Packaged in Impermeable Containers 11 C. Drag Products Packaged in Semipermeable Containers 11 D. Drag Products Intended for Storage in a Refrigerator 12 E. Drag Products Intended for Storage in a Freezer 13 F. Drag Products Intended for Storage below -20"C 13 IV Glossary 14 References 1() Chapter 3 Container Closure Systems '7 I. Introduction '7 A. Definitions '7 B. Current Good Manufacturing Practice, the Consumer Product Safety Commission, and Requirements on Containers and Closures 17 C. Additional Considerations 17 II. Qualification and Quality Control of Packaging Components 18 A. Description 21 B. Information about Suitability 21 C. Stability Data (Packaging Concerns) 22 D. Inhalation Drag Products 23 E. Injection and Ophthalmic Drag Products 23 F.
    [Show full text]
  • Identification and Characterization of Phenolics from Ethanolic Extracts of Phyllanthus Species by HPLC-ESI-QTOF-MS/MS
    Author’s Accepted Manuscript Identification and characterization of phenolics from ethanolic extracts of Phyllanthus species by HPLC-ESI-QTOF-MS/MS Sunil Kumar, Awantika Singh, Brijesh Kumar www.elsevier.com/locate/jpa PII: S2095-1779(17)30016-3 DOI: http://dx.doi.org/10.1016/j.jpha.2017.01.005 Reference: JPHA347 To appear in: Journal of Pharmaceutical Analysis Received date: 25 June 2016 Revised date: 13 January 2017 Accepted date: 17 January 2017 Cite this article as: Sunil Kumar, Awantika Singh and Brijesh Kumar, Identification and characterization of phenolics from ethanolic extracts of Phyllanthus species by HPLC-ESI-QTOF-MS/MS, Journal of Pharmaceutical Analysis, http://dx.doi.org/10.1016/j.jpha.2017.01.005 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Identification and characterization of phenolics from ethanolic extracts of Phyllanthus species by HPLC-ESI-QTOF-MS/MS Sunil Kumara, Awantika Singha,b, Brijesh Kumara,b* aSophisticated Analytical Instrument Facility, CSIR-Central Drug Research Institute, Lucknow- 226031, Uttar Pradesh, India bAcademy of Scientific and Innovative Research (AcSIR), New Delhi-110025, India [email protected] [email protected] *Corresponding author at: Sophisticated Analytical Instrument Facility, CSIR-Central Drug Research Institute, Lucknow-226031.
    [Show full text]
  • Neuroprotective Mechanisms of Three Natural Antioxidants on a Rat Model of Parkinson's Disease: a Comparative Study
    antioxidants Article Neuroprotective Mechanisms of Three Natural Antioxidants on a Rat Model of Parkinson’s Disease: A Comparative Study Lyubka P. Tancheva 1,*, Maria I. Lazarova 2 , Albena V. Alexandrova 3, Stela T. Dragomanova 1,4, Ferdinando Nicoletti 5 , Elina R. Tzvetanova 3, Yordan K. Hodzhev 6, Reni E. Kalfin 2, Simona A. Miteva 1, Emanuela Mazzon 7 , Nikolay T. Tzvetkov 8 and Atanas G. Atanasov 2,9,10,11,* 1 Department of Behavior Neurobiology, Institute of Neurobiology, Bulgarian Academy of Sciences, Sofia 1113, Bulgaria; [email protected] (S.T.D.); [email protected] (S.A.M.) 2 Department of Synaptic Signaling and Communications, Institute of Neurobiology, Bulgarian Academy of Sciences, Sofia 1113, Bulgaria; [email protected] (M.I.L.); reni_kalfi[email protected] (R.E.K.) 3 Department Biological Effects of Natural and Synthetic Substances, Institute of Neurobiology, Bulgarian Academy of Sciences, Sofia 1113, Bulgaria; [email protected] (A.V.A.); [email protected] (E.R.T.) 4 Department of Pharmacology, Toxicology and Pharmacotherapy, Faculty of Pharmacy, Medical University, Varna 9002, Bulgaria 5 Department of Biomedical and Biotechnological Sciences, University of Catania, Via S. Sofia 89, 95123 Catania, Italy; [email protected] 6 Department of Sensory Neurobiology, Institute of Neurobiology, Bulgarian Academy of Sciences, Sofia 1113, Bulgaria; [email protected] 7 IRCCS Centro Neurolesi “Bonino-Pulejo”, Via Provinciale Palermo, Contrada Casazza, 98124 Messina, Italy; [email protected] 8 Department of Biochemical
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0143022 A1 Wicker Et Al
    US 20170143022A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0143022 A1 Wicker et al. (43) Pub. Date: May 25, 2017 (54) COMPOSITIONS INCORPORATING AN (52) U.S. Cl. UMLAM FLAVORAGENT CPC ............... A2.3L 27/20 (2016.08); A23L 27/88 (2016.08); A23L 2/56 (2013.01); A23L 2780 (71) Applicant: Senomyx, Inc., San Diego, CA (US) (2016.08); A23L 27/30 (2016.08); A23K 20/10 (2016.05); A23K 50/40 (2016.05); A61K 47/22 (72) Inventors: Sharon Wicker, Carlsbad, CA (US); (2013.01) Tanya Ditschun, San Diego, CA (US) (21) Appl. No.: 14/948,101 (57) ABSTRACT The present invention relates to compositions containing (22) Filed: Nov. 20, 2015 flavor or taste modifiers, such as a flavoring or flavoring agents and flavor or taste enhancers, more particularly, Publication Classification savory (“umami”) taste modifiers, savory flavoring agents (51) Int. Cl. and savory flavor enhancers, for foods, beverages, and other AOIN 25/00 (2006.01) comestible compositions. Compositions comprising an A23K2O/It (2006.01) umami flavor agent or umami taste-enhancing agent in A6 IK 47/22 (2006.01) combination with one or more other food additives, prefer A2.3L 2/56 (2006.01) ably including a flavorant, herb, Spice, fat, or oil, are A23K 50/40 (2006.01) disclosed. US 2017/O 143022 A1 May 25, 2017 COMPOSITIONS INCORPORATING AN tions WO 02/06254, WO 00/63166 art, WO 02/064631, and UMAM FLAVORAGENT WO 03/001876, and U.S. Patent publication US 2003 0232407 A1. The entire disclosures of the articles, patent BACKGROUND OF THE INVENTION applications,
    [Show full text]
  • NON-HAZARDOUS CHEMICALS May Be Disposed of Via Sanitary Sewer Or Solid Waste
    NON-HAZARDOUS CHEMICALS May Be Disposed Of Via Sanitary Sewer or Solid Waste (+)-A-TOCOPHEROL ACID SUCCINATE (+,-)-VERAPAMIL, HYDROCHLORIDE 1-AMINOANTHRAQUINONE 1-AMINO-1-CYCLOHEXANECARBOXYLIC ACID 1-BROMOOCTADECANE 1-CARBOXYNAPHTHALENE 1-DECENE 1-HYDROXYANTHRAQUINONE 1-METHYL-4-PHENYL-1,2,5,6-TETRAHYDROPYRIDINE HYDROCHLORIDE 1-NONENE 1-TETRADECENE 1-THIO-B-D-GLUCOSE 1-TRIDECENE 1-UNDECENE 2-ACETAMIDO-1-AZIDO-1,2-DIDEOXY-B-D-GLYCOPYRANOSE 2-ACETAMIDOACRYLIC ACID 2-AMINO-4-CHLOROBENZOTHIAZOLE 2-AMINO-2-(HYDROXY METHYL)-1,3-PROPONEDIOL 2-AMINOBENZOTHIAZOLE 2-AMINOIMIDAZOLE 2-AMINO-5-METHYLBENZENESULFONIC ACID 2-AMINOPURINE 2-ANILINOETHANOL 2-BUTENE-1,4-DIOL 2-CHLOROBENZYLALCOHOL 2-DEOXYCYTIDINE 5-MONOPHOSPHATE 2-DEOXY-D-GLUCOSE 2-DEOXY-D-RIBOSE 2'-DEOXYURIDINE 2'-DEOXYURIDINE 5'-MONOPHOSPHATE 2-HYDROETHYL ACETATE 2-HYDROXY-4-(METHYLTHIO)BUTYRIC ACID 2-METHYLFLUORENE 2-METHYL-2-THIOPSEUDOUREA SULFATE 2-MORPHOLINOETHANESULFONIC ACID 2-NAPHTHOIC ACID 2-OXYGLUTARIC ACID 2-PHENYLPROPIONIC ACID 2-PYRIDINEALDOXIME METHIODIDE 2-STEP CHEMISTRY STEP 1 PART D 2-STEP CHEMISTRY STEP 2 PART A 2-THIOLHISTIDINE 2-THIOPHENECARBOXYLIC ACID 2-THIOPHENECARBOXYLIC HYDRAZIDE 3-ACETYLINDOLE 3-AMINO-1,2,4-TRIAZINE 3-AMINO-L-TYROSINE DIHYDROCHLORIDE MONOHYDRATE 3-CARBETHOXY-2-PIPERIDONE 3-CHLOROCYCLOBUTANONE SOLUTION 3-CHLORO-2-NITROBENZOIC ACID 3-(DIETHYLAMINO)-7-[[P-(DIMETHYLAMINO)PHENYL]AZO]-5-PHENAZINIUM CHLORIDE 3-HYDROXYTROSINE 1 9/26/2005 NON-HAZARDOUS CHEMICALS May Be Disposed Of Via Sanitary Sewer or Solid Waste 3-HYDROXYTYRAMINE HYDROCHLORIDE 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen Et Al
    USOO8603526B2 (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen et al. (45) Date of Patent: Dec. 10, 2013 (54) PHARMACEUTICAL COMPOSITIONS 2008. O152595 A1 6/2008 Emigh et al. RESISTANT TO ABUSE 2008. O166407 A1 7/2008 Shalaby et al. 2008/0299.199 A1 12/2008 Bar-Shalom et al. 2008/0311205 A1 12/2008 Habib et al. (75) Inventors: Peter Holm Tygesen, Smoerum (DK); 2009/0022790 A1 1/2009 Flath et al. Jan Martin Oevergaard, Frederikssund 2010/0203129 A1 8/2010 Andersen et al. (DK); Karsten Lindhardt, Haslev (DK); 2010/0204259 A1 8/2010 Tygesen et al. Louise Inoka Lyhne-versen, Gentofte 2010/0239667 A1 9/2010 Hemmingsen et al. (DK); Martin Rex Olsen, Holbaek 2010, O291205 A1 11/2010 Downie et al. (DK); Anne-Mette Haahr, Birkeroed 2011 O159100 A1 6/2011 Andersen et al. (DK); Jacob Aas Hoellund-Jensen, FOREIGN PATENT DOCUMENTS Frederikssund (DK); Pemille Kristine Hoeyrup Hemmingsen, Bagsvaerd DE 20 2006 014131 1, 2007 (DK) EP O435,726 8, 1991 EP O493513 7, 1992 EP O406315 11, 1992 (73) Assignee: Egalet Ltd., London (GB) EP 1213014 6, 2002 WO WO 89,09066 10, 1989 (*) Notice: Subject to any disclaimer, the term of this WO WO91,040 15 4f1991 patent is extended or adjusted under 35 WO WO95/22962 8, 1995 U.S.C. 154(b) by 489 days. WO WO99,51208 10, 1999 WO WOOOf 41704 T 2000 WO WO 03/024426 3, 2003 (21) Appl. No.: 12/701,429 WO WOO3,O24429 3, 2003 WO WOO3,O24430 3, 2003 (22) Filed: Feb.
    [Show full text]
  • Article (Published Version)
    Article Characterization of drug‐induced transcriptional modules: towards drug repositioning and functional understanding ISKAR, Murat, et al. Reference ISKAR, Murat, et al. Characterization of drug‐induced transcriptional modules: towards drug repositioning and functional understanding. Molecular Systems Biology, 2013, vol. 9, no. 1, p. 662 DOI : 10.1038/msb.2013.20 PMID : 23632384 Available at: http://archive-ouverte.unige.ch/unige:153825 Disclaimer: layout of this document may differ from the published version. 1 / 1 Molecular Systems Biology 9; Article number 662; doi:10.1038/msb.2013.20 Citation: Molecular Systems Biology 9:662 www.molecularsystemsbiology.com Characterization of drug-induced transcriptional modules: towards drug repositioning and functional understanding Murat Iskar1, Georg Zeller1, Peter Blattmann2,3, Monica Campillos4,5, Michael Kuhn6, Katarzyna H Kaminska1,9, Heiko Runz3,7, Anne-Claude Gavin1, Rainer Pepperkok2,3, Vera van Noort1 and Peer Bork1,8,* 1 Structural and Computational Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany, 2 Cell Biology/Biophysics Unit, EMBL, Heidelberg, Germany, 3 Molecular Medicine Partnership Unit (MMPU), EMBL, University of Heidelberg, Heidelberg, Germany, 4 Institute for Bioinformatics and Systems Biology, Helmholtz Center Munich–German Research Center for Environmental Health (GmbH), Neuherberg, Germany, 5 German Center for Diabetes Research (DZD), Neuherberg, Germany, 6 Biotechnology Center, TU Dresden, Dresden, Germany, 7 Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany and 8 Max-Delbru¨ck-Centre for Molecular Medicine, Berlin, Germany 9Present address: International Institute of Molecular and Cell Biology in Warsaw, ul. Ks. Trojdena 4, 02-109 Warsaw, Poland * Corresponding author. Structural and Computational Biology Unit, European Molecular Biology Laboratory (EMBL), Meyerhofstrasse 1, Heidelberg, Germany.
    [Show full text]
  • Etats Rapides
    List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate
    [Show full text]
  • Pharmacology on Your Palms CLASSIFICATION of the DRUGS
    Pharmacology on your palms CLASSIFICATION OF THE DRUGS DRUGS FROM DRUGS AFFECTING THE ORGANS CHEMOTHERAPEUTIC DIFFERENT DRUGS AFFECTING THE NERVOUS SYSTEM AND TISSUES DRUGS PHARMACOLOGICAL GROUPS Drugs affecting peripheral Antitumor drugs Drugs affecting the cardiovascular Antimicrobial, antiviral, Drugs affecting the nervous system Antiallergic drugs system antiparasitic drugs central nervous system Drugs affecting the sensory Antidotes nerve endings Cardiac glycosides Antibiotics CNS DEPRESSANTS (AFFECTING THE Antihypertensive drugs Sulfonamides Analgesics (opioid, AFFERENT INNERVATION) Antianginal drugs Antituberculous drugs analgesics-antipyretics, Antiarrhythmic drugs Antihelminthic drugs NSAIDs) Local anaesthetics Antihyperlipidemic drugs Antifungal drugs Sedative and hypnotic Coating drugs Spasmolytics Antiviral drugs drugs Adsorbents Drugs affecting the excretory system Antimalarial drugs Tranquilizers Astringents Diuretics Antisyphilitic drugs Neuroleptics Expectorants Drugs affecting the hemopoietic system Antiseptics Anticonvulsants Irritant drugs Drugs affecting blood coagulation Disinfectants Antiparkinsonian drugs Drugs affecting peripheral Drugs affecting erythro- and leukopoiesis General anaesthetics neurotransmitter processes Drugs affecting the digestive system CNS STIMULANTS (AFFECTING THE Anorectic drugs Psychomotor stimulants EFFERENT PART OF THE Bitter stuffs. Drugs for replacement therapy Analeptics NERVOUS SYSTEM) Antiacid drugs Antidepressants Direct-acting-cholinomimetics Antiulcer drugs Nootropics (Cognitive
    [Show full text]
  • Department of Health
    DEPARTMENT OF HEALTH National Drug Policy - Pharmaceutical Management Unit 50 National Formulary Committee Philippine National Drug Formulary EssentialEssential MedicinesMedicines ListList Volume I, 7th Edition ( 2008 ) Published by: The National Formulary Committee National Drug Policy ‐ Pharmaceutical Management Unit 50 DEPARTMENT OF HEALTH Manila, Philippines All rights reserved 2008 The National Formulary Committee National Drug Policy‐Pharmaceutical Management Unit 50 (NDP‐PMU 50) Department of Health San Lazaro Cmpd., Rizal Ave., Sta. Cruz, Manila, Philippines 1003 ISBN 978‐971‐91620‐7‐0 Any part or the whole book may be reproduced or transmitted without any alteration, in any form or by any means, with permission from DOH provided it is not sold commercially. ii PHILIPPINE NATIONAL DRUG FORMULARY Volume I, 7th Edition 2 0 0 8 Francisco T. Duque III, MD, MSc Secretary of Health Alexander A. Padilla Undersecretary of Health, Office for External Affairs Robert Louie P. So, MD Program Manager, NDP-PMU 50 Dennis S. Quiambao, MD Proj. Mgmt. Operating Officer & Coordinator (PMOOC) NDP-PMU 50 NATIONAL FORMULARY COMMITTEE Estrella B. Paje-Villar, MD, DTM & H Chairperson Jose M. Acuin, MD, MSc Alma L. Jimenez, MD Alejandro C. Baroque II, MD Marieta B. de Luna, MD Bu C. Castro, MD Nelia P. Cortes-Maramba, MD Dina V. Diaz, MD Yolanda R. Robles, PhD Pharm Mario R. Festin, MD, MS, MHPEd Isidro C. Sia, MD BFAD Representative SECRETARIAT Luzviminda O. Marquez, RPh, RMT Mary Love C. Victoria, RPh Michael D. Junsay, RPh Ermalyn M. Magturo iii Republic of the Philippines DEPARTMENT OF HEALTH OFFICE OF THE SECRETARY 2/F Bldg. 1, San Lazaro Cmpd., Rizal Avenue, Sta.
    [Show full text]